# OX Alpha task: round67_final_closure

- Timestamp: 2026-08-22T03:22:54.324507+00:00
- Model: stealth/ox-alpha
- Elapsed: 109.44s
- Finish reason: stop
- Usage: {"prompt_tokens": 2238, "completion_tokens": 3063, "total_tokens": 5301, "cost": 0, "is_byok": false, "prompt_tokens_details": {"cached_tokens": 64, "cache_write_tokens": 0, "audio_tokens": 0, "video_tokens": 0}, "cost_details": {"upstream_inference_cost": 0, "upstream_inference_prompt_cost": 0, "upstream_inference_completions_cost": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "image_tokens": 0, "audio_tokens": 0}}

## User prompt

```
You are performing the FINAL PRIOR-ART CLOSURE ASSESSMENT for Round 67. The CTO must decide: are all zero-cost prior-art checks now complete, or are there remaining unresolved vectors?

CEO ROUND 66 DIRECTIVE:
"Finish the two remaining zero-cost prior-art checks, then stop coding. The next decisive step is experimental reality."

The two checks:
1. Fetch and claim-map CN122376206A (failed in Round 66 — resolved this round via Patsnap alternate source)
2. Targeted traction-velocity search using CEO's exact terms + inventor/family/citation network

============================================================
CHECK 1 RESULTS: CN122376206A (fetched from Patsnap Eureka)
============================================================

Title: "Apparatus and method for controlled clot aspiration"
Text extracted: 240,177 chars

KEYWORD FINDINGS:
- "predict" (10 occurrences): "the algorithm then refers to these datasets to interpret previously unseen pressure readings to PREDICT THE CATHETER'S STATE" and "utilizes an artificial neural net[work]"
- "velocity" (6 occurrences): refers to FLOW VELOCITY within connecting tube, NOT traction velocity
- "speed" (2 occurrences): "speed of the beep" (auditory feedback), NOT pull speed
- "rate" (209 occurrences): overwhelmingly "flow rate" and "pressure rate" — aspiration parameters
- "control" (316), "flow" (362), "sensor" (109), "algorithm" (98), "automatic" (45), "blockage" (42), "pulse" (200)
- "pull" (2): "pulling the clots or obstructing material out along with the catheter" — describes manual removal, not controlled pull velocity
- "fragment" / "fragmentation": NOT found in the keyword scan

ASSESSMENT OF CN122376206A:
- Teaches: sensor (flow rate + pressure) -> algorithm (predicts catheter state: clotted vs unclotted) -> automatic control (pressure pulses, aspiration cycles)
- This is SENSOR -> PREDICTIVE ALGORITHM -> AUTOMATIC CONTROL in thrombectomy
- BUT: the prediction target is CATHETER STATE (clotted/unclotted), NOT clot FRAGMENTATION
- The actuator is ASPIRATION PRESSURE/FLOW, NOT traction velocity
- The "predict" language is about classifying current catheter state from pressure readings, NOT about predicting a future adverse event

CRITICAL QUESTION: Does CN122376206A's "predict the catheter's state" constitute forward prediction of an adverse event?
- NO — it predicts the CURRENT state (is the catheter blocked or not?) from pressure data, not a FUTURE event
- This is classification/pattern recognition, not time-series forecasting
- However, it does establish that PREDICTIVE ALGORITHMS (including neural networks) are known in thrombectomy control systems

============================================================
CHECK 2 RESULTS: TARGETED TRACTION-VELOCITY SEARCH
============================================================

12 queries using CEO's exact terms:
- "retrieval velocity", "traction speed", "pull speed", "displacement control"
- "servo traction", "motorized thrombectomy retrieval", "velocity feedback", "force-velocity control"
- Plus inventor/family network terms (Stryker, Imperative Care) and robotics-assisted vascular intervention

23 patent hits identified. Analysis of velocity-related language:
- ONLY 2 hits with velocity-related language:
  * US6,090,118: "rotation speed of the wire" — ROTATIONAL thrombectomy (rotational speed, NOT linear traction velocity)
  * US10531883B1: "step in speed is in a range from 1 Hz to approximately 4 Hz" — VALVE CYCLING FREQUENCY (Hz), NOT linear pull velocity
- ZERO hits teach linear traction-VELOCITY modulation during thrombectomy retrieval based on sensor feedback
- 21 remaining hits teach force/flow/pressure/vacuum control (already known from prior rounds)

============================================================
YOUR ASSESSMENT — produce these sections:
============================================================

SECTION 1: CN122376206A CLOSURE

Does CN122376206A:
(a) Teach forward prediction of an adverse event (fragmentation, embolization)? YES / NO
(b) Teach traction-VELOCITY modulation? YES / NO
(c) Strengthen the §103 combination attack against the candidate? YES / NO — explain how
(d) Close the INCONCLUSIVE status from Round 66? YES / NO

SECTION 2: TRACTION-VELOCITY SEARCH CLOSURE

Does the targeted search (12 queries, 23 patent hits):
(a) Find any patent teaching linear traction-VELOCITY modulation during thrombectomy? YES / NO
(b) Find any patent teaching motorized/servo-controlled pull speed? YES / NO
(c) Close the "direct traction-velocity landscape" uncertainty? YES / NO
(d) If NO to (a) and (b): is the absence of traction-velocity teaching in 23 hits sufficient to conclude the actuator is NOT taught in the searched landscape?

SECTION 3: REMAINING UNCERTAINTY VECTORS

After Round 67, are there any remaining zero-cost prior-art uncertainty vectors? List them or state "NONE — all zero-cost checks complete."

Specifically assess:
- CN122376206A: RESOLVED or still INCONCLUSIVE?
- Direct traction-velocity prior art: RESOLVED or still INCONCLUSIVE?
- Adjacent-field (endarterectomy, stone-basket, biopsy): was this searched? If not, is it a remaining vector?
- Inventor/family/citation network: was this followed? If not, is it a remaining vector?

SECTION 4: §103 GATE STATUS UPDATE

After Round 67:
- Is the §103 gate still OPEN, or has it been partially closed?
- What is the strongest remaining §103 combination attack?
- What is the candidate's strongest defense against that attack?

SECTION 5: PRIOR-ART CLOSURE VERDICT

- ALL ZERO-COST CHECKS COMPLETE: All computationally tractable prior-art analysis is finished. The candidate's legal novelty status is as established as it can be without wet-lab evidence. The next step is experimental.
- REMAINING ZERO-COST CHECKS: List what is still unresolved and should be done before stopping.
- STOP CODING: The prior-art search is substantially complete. Further software analysis will not resolve the §103 question or the physics question. The next decisive step is experimental reality.

SECTION 6: PHYSICS GATE DESIGN (adversarial, per CEO directive)

Per CEO: "The wet-lab design must test: fresh thrombus, different fibrin/RBC compositions, different clot lengths, realistic flow, curvature, device motion, traction velocities, aspiration pressures. And the analysis must be blinded to the fracture outcome during feature selection."

Draft the physics gate experimental design:
- What samples (fresh thrombus, compositions, lengths)?
- What sensing (force, impedance, acoustic, optical)?
- What conditions (flow, curvature, device motion, traction velocities, aspiration pressures)?
- What is the primary endpoint (lead time to fragmentation)?
- What is the blinding protocol (feature selection blinded to fracture outcome)?
- What are the 6 pre-registered kill conditions (from Round 66)?
- What statistical analysis plan?

This is the LAST software step before wet-lab. Make it adversarial and complete.

CONSTRAINTS:
- Be honest. Do not claim closure if uncertainty remains.
- Do NOT use semantic distinctions as novelty loopholes (CE-012).
- Mark INCONCLUSIVE where evidence is insufficient.
- Per CE-018 sharpened: assess at the complete causal loop level.

Target ~2000-2500 words.

```

## Response (content)

ROUND 67 — FINAL PRIOR-ART CLOSURE ASSESSMENT

============================================================
SECTION 1: CN122376206A CLOSURE
============================================================

(a) Teach forward prediction of an adverse event (fragmentation, embolization)? NO.
The "predict the catheter's state" language is state classification from current pressure readings (clotted vs. unclotted), not time-series forecasting of a future adverse event. The prediction target is present-state, not future-outcome.

(b) Teach traction-VELOCITY modulation? NO.
All velocity/rate/speed language maps to aspiration flow rate, pressure pulses, and auditory feedback cadence. The actuator is aspiration pressure/flow. The two "pull" occurrences describe manual catheter withdrawal, not controlled pull velocity.

(c) Strengthen the §103 combination attack? YES — moderately.
It strengthens the GENERAL-motivation prong: it establishes that sensor -> predictive algorithm (including neural network) -> automatic closed-loop control is known and obvious in thrombectomy systems. An examiner could argue that substituting the prediction target (fragmentation risk) and the actuator (traction velocity) into an otherwise-known architecture is routine optimization. It does NOT supply either element itself: no forward adverse-event prediction, no traction actuator.

(d) Close the INCONCLUSIVE status from Round 66? YES.
The document has been fetched (240k chars), keyword-mapped, and claim-relevant passages assessed. Status changes INCONCLUSIVE -> RESOLVED (non-teaching for both candidate elements; partial §103 motivation support).

Caveat per CE-012: I flag that "predicts CURRENT state" vs. "predicts FUTURE event" is a semantic distinction. The honest framing: CN122376206A does not teach forecasting, but it makes the *concept of algorithmic prediction in thrombectomy* non-novel. The candidate cannot rest on "prediction exists" as its contribution — only on the specific predicted quantity (fragmentation lead-time) and the specific causal loop (sensed traction dynamics -> velocity modulation). This must be defended at the complete-loop level (CE-018), not at the word level.

============================================================
SECTION 2: TRACTION-VELOCITY SEARCH CLOSURE
============================================================

(a) Any patent teaching linear traction-velocity modulation during thrombectomy? NO.
(b) Any patent teaching motorized/servo-controlled pull speed in thrombectomy retrieval? NO among the 23 hits. US6,090,118 teaches rotational speed control (different axis of motion); US10531883B1 teaches valve cycling frequency (not displacement control).
(c) Does this close the "direct traction-velocity landscape" uncertainty? PARTIALLY.
(d) Is absence across 23 hits sufficient to conclude the actuator is NOT taught? NO — with an important qualification.

Honest assessment: 23 hits from 12 well-formed queries (CEO terms + inventor/family/citation vocabulary) is a genuine negative signal, but query-fragility (CE-014) means absence-of-hits is weaker evidence than presence-of-hits. Two specific residual risks:

1. Adjacent-field vocabulary gap. Linear traction of a captured object under force feedback is core technology in stone basketing (ureteroscopy), mechanical thrombectomy of the *venous* system, endarterectomy plaque stripping, and biopsy forceps actuation. These fields use different inventor vocabulary ("extraction rate," "withdrawal profile," "disengagement force," "basket retraction") that was NOT in the 12 queries. A patent teaching servo-controlled basket retraction with force feedback would be directly §103-relevant and would not surface under thrombectomy-specific queries.

2. Robotics-assisted vascular intervention. The search touched this but robotic catheter platforms (e.g., Corindus-lineage, Hansen Medical lineage) teach motorized catheter translation with position/force servo loops. Whether any teaches *clot-traction-specific* velocity profiles is unresolved. UNKNOWN whether a specific citation exists; I will not fabricate one.

Verdict: the direct landscape is RESOLVED to the limit of thrombectomy-native vocabulary; the adjacent-field vector remains OPEN.

============================================================
SECTION 3: REMAINING UNCERTAINTY VECTORS
============================================================

- CN122376206A: RESOLVED.
- Direct traction-velocity prior art (thrombectomy-native): RESOLVED (negative, with CE-014 caveat noted above).
- Adjacent-field search (endarterectomy, ureteroscopic stone baskets, biopsy actuation, venous thrombectomy): NOT SEARCHED. REMAINING VECTOR. This is zero-cost (patent database queries only) and should be executed before closure. Estimated effort: 6-8 queries using adjacent-field CPC classes (A61B 17/22 variants, A61B 17/3200 series, A61M 25/01) plus extraction/traction vocabulary native to those fields.
- Inventor/family/citation network: PARTIALLY followed (Stryker, Imperative Care named in queries). Not exhaustively forward-cited. Forward citation tracing from US10531883B1 family and CN122376206A family is a remaining zero-cost vector, though lower yield given the negative direct search.
- Non-patent literature (conference proceedings, e.g., vascular intervention engineering literature): not searched. Marginal vector; patents dominate this space. Optional.

Net: TWO remaining zero-cost vectors (adjacent-field queries; forward-citation trace), one optional (NPL).

============================================================
SECTION 4: §103 GATE STATUS UPDATE
============================================================

Status: PARTIALLY CLOSED — still OPEN.

What Round 67 accomplished:
- Removed the largest single-document uncertainty (CN122376206A).
- Established a genuine negative result on the traction-velocity actuator within thrombectomy-native prior art.

Strongest remaining §103 combination attack:
Primary reference: a thrombectomy system teaching sensor-based automatic aspiration control (CN122376206A-type or the flow/vacuum-control references from earlier rounds, IDs established in Rounds <66).
Secondary reference: ANY motorized/servo catheter-positioning system teaching linear translation with feedback (robotic vascular intervention or adjacent-field extraction device).
Attack narrative: "Combine the known predictive-control architecture with the known motorized-retraction actuator; choosing fragmentation-risk as the controlled variable and pull velocity as the manipulated variable is routine design choice by a POSITA." The motivation-to-combine is strengthened by CN122376206A's explicit use of neural-network prediction in this exact device class.

Candidate's strongest defense:
At the complete causal loop level (CE-018): no cited reference closes the loop [sensed traction-force/displacement dynamics during clot engagement] -> [forward prediction of fragmentation/embolization with quantified lead time] -> [closed-loop modulation of linear traction velocity] -> [verified reduction in fragmentation incidence]. Each element individually may be arguable as known; the specific coupling — particularly the claim that traction-dynamics features carry fragmentation-predictive information with usable lead time — is an empirical physics claim, not a design-choice claim. If the physics is false, the combination fails for inoperability; if true, the question becomes whether it was obvious to test. That is precisely what the wet-lab gate resolves.

Strongest alternative explanation (Article XXXII duty): the negative traction-velocity search result may reflect terminology mismatch rather than genuine absence — i.e., the actuator IS taught somewhere under different vocabulary. This is exactly why Section 3's adjacent-field check matters before declaring victory.

============================================================
SECTION 5: PRIOR-ART CLOSURE VERDICT
============================================================

REMAINING ZERO-COST CHECKS (do these before stopping):

1. Adjacent-field traction/extraction search (MANDATORY):
   - Ureteroscopic stone-basket retrieval: queries using "basket retraction," "stone disengagement," "extraction force feedback," CPC A61B 17/221, A61B 17/94.
   - Endarterectomy: "plaque stripping," "shunt flow," "endarterectomy endpoint," CPC A61B 17/32053 vicinity.
   - Robotic vascular platforms: "catheter manipulator," "linear stage catheter," "proximal actuation," CPC A61B 34/30, A61B 34/32.
   - Venous/large-vessel thrombectomy: "large bore aspiration," "clot maceration."
   - Acceptance criterion: if any hit teaches servo-controlled LINEAR retraction of an intravascular capture device with force feedback, the §103 attack upgrades materially and the verdict changes.

2. Forward-citation trace (RECOMMENDED, low cost): cite-forward from the US10531883B1 family and CN122376206A family; scan titles/abstracts for traction/velocity/retraction language.

3. NPL sweep (OPTIONAL): skip unless items 1-2 produce leads.

After items 1-2 return clean: verdict becomes ALL ZERO-COST CHECKS COMPLETE, and the next decisive step is experimental reality. Do not extend software analysis beyond that point; further searching has diminishing returns and the binding uncertainties are physical (does the signal exist?) and legal (obviousness judgment), neither resolvable by more code.

============================================================
SECTION 6: PHYSICS GATE DESIGN (ADVERSARIAL)
============================================================

Design principle: every ideal assumption relaxed toward realistic physics (CE-017); implementation failure separated from mechanism failure (Art. XXIX); feature selection blinded to outcome.

6.1 SAMPLES
- Fresh porcine or bovine blood thrombus formed ex vivo within 24 h of experiment; never re-frozen more than once; aged cohorts at 6 h / 24 h / 72 h to span fibrin-rich vs. RBC-rich composition.
- Composition matrix: (i) RBC-rich (static stasis clot), (ii) fibrin-rich (flow-formed clot via Chandler loop), (iii) mixed. Minimum n=10 clots per cell, 3 compositions x 3 ages = 90 clots minimum; power analysis to be run before freezing the protocol.
- Lengths: short (<10 mm), medium (10-20 mm), long (>20 mm, vessel-segment scale).
- Negative controls: gelatin/agar phantoms (known non-fragmenting) to verify sensing chain does not produce false-positive fracture signatures.

6.2 SENSING (multi-modal, so mechanism failure is distinguishable from sensor failure)
- Proximal axial force + displacement at the traction actuator (the primary candidate feature source).
- Aspiration line pressure + flow (confound channel — must be recorded even if not used, to rule out alternative explanations).
- High-speed optical imaging through transparent vessel mockup (ground truth for fragmentation onset and embolic particle release).
- Acoustic emission (optional tertiary channel; do not let its presence dilute the primary hypothesis).

6.3 CONDITIONS (adversarial relaxation of each ideal assumption)
- Flow: pulsatile physiological flow (not static), including reduced-flow states.
- Curvature: straight tube AND >=90-degree bend AND tortuous phantom.
- Device motion: include operator-style jiggle/advancement during traction, not pure axial pull.
- Traction velocities: swept range spanning gentle manual withdrawal to aggressive pull; randomized order.
- Aspiration pressures: crossed factor at low/high vacuum.
- Full factorial is infeasible; use a fractional factorial / response-surface design over {composition, length, curvature, velocity, vacuum} with flow and motion held at two levels each.

6.4 PRIMARY ENDPOINT
Lead time: interval between earliest statistically detectable change in traction-signal features and optically confirmed first fragmentation/embolic release. Secondary endpoints: fragmentation incidence rate per condition; emboli count/size distribution.

Success threshold (pre-registered): median lead time significantly > 0 with a lower confidence bound exceeding the minimum actuator response latency (measured separately for the proposed velocity-modulation hardware). If lead time exists but is shorter than achievable actuator response, the mechanism is real but the invention is inoperative — record as such.

6.5 BLINDING PROTOCOL
- Feature selection performed ONLY on a development split whose fracture labels are sealed by an independent party.
- Features frozen in writing before label unsealing; then evaluated on a held-out split.
- All trials randomized and interleaved so the experimenter running the rig cannot infer condition ordering.
- Ground-truth fragmentation scoring done by two blinded reviewers from video; disagreements adjudicated by a third.

6.6 SIX PRE-REGISTERED KILL CONDITIONS (from Round 66, restated and made falsifiable)
K1: No traction-signal feature shows any change preceding fragmentation beyond chance (permutation test p > 0.05 after correction) — the predictive signal does not exist.
K2: Signal exists only in idealized conditions (straight tube, static fluid, pristine clots) and vanishes under realistic flow/curvature/motion — not robust.
K3: Lead time is shorter than physically achievable actuator response latency — unactionable.
K4: Signal is fully explained by already-measured aspiration pressure/flow (i.e., adds no information beyond existing sensors) — redundant, no new measurement needed.
K5: Fragmentation incidence is dominated by composition/age factors unrelated to traction dynamics, and conditioning on traction features does not reduce incidence — wrong causal lever.
K6: Reproducibility failure: effect does not replicate across independent clot batches/operators — artifact.

Any single kill condition met: mechanism killed for that embodiment class; per Art. XXIX, document which assumption failed before considering alternate embodiments.

6.7 STATISTICAL ANALYSIS PLAN
- Primary: survival-analysis style (time-to-event) comparing pre-fragmentation feature deviation against null via block permutation on trial ID; report effect size with CI, not just p-value.
- Multiple comparisons: pre-register the small primary feature family; exploratory channels labeled as such.
- Mixed-effects model with clot batch and day as random effects to separate reproducibility from condition effects.
- Pre-registration document signed and timestamped before first trial; deviations logged explicitly.

============================================================
BOTTOM LINE FOR THE CTO
============================================================
Two mandatory zero-cost checks remain (adjacent-field extraction-device search; forward-citation trace). Execute them; if they return clean, declare ALL ZERO-COST CHECKS COMPLETE and move immediately to the wet-lab physics gate as designed above. The §103 gate remains partially open pending those results; the decisive uncertainties thereafter are physical, not textual.

---

## Reasoning (for audit)

Produce structured assessment, ~2000-2500 words.
